A glance to the unique facility which enables a variety of environmental studies in the lab.
Worldwide exclusive: A first-ever visit to the Israel Institute for Biological Research and an interview with its director, Col. (res.) Prof. Shmuel Shapira, who sheds some light on the secrets and operations of the mysterious institute.
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a research and development collaboration with the Israel Institute for Biological Research (“IIBR”) to further advance its C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, to combat emerging diseases and threats.
We welcome you to contact us for any question or offer for collaborations.
Enter your full name please.
Choose your country phone code.
Enter your phone number.
Enter your e-mail address.
Select the derpartment you wish to contact with.
If you have any message to deliver, please write it here.
There are some errors in your form.
the mail is recived, thank you